Viracta Therapeutics Inc. (VIRX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now
Sunesis (VIRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?
Viracta Therapeutics (NASDAQ: VIRX ) stock is heading higher on Wednesday after the clinical-stage precision oncology company released its Q2 earnings report. The first bit of news boosting VIRX stock higher is its diluted earnings per share of -25 cents.
Viracta Therapeutics Inc. (VIRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Viracta Therapeutics Inc. ever had a stock split?
Viracta Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Craig R. Jalbert CEO | NASDAQ (CM) Exchange | 92765F108 CUSIP |
| US Country | 26 Employees | - Last Dividend | 25 Feb 2021 Last Split | - IPO Date |
Overview
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company dedicated to the mission of treating and preventing virus-associated cancers across the globe. The company has pinpointed a niche yet critical area of oncology, leveraging the connection between viruses and the development of specific cancer types. By focusing on virus-associated cancers, Viracta aims to provide targeted therapies for patients suffering from these complex diseases. The foundation of Viracta's innovative approach lies in its groundbreaking research and development efforts, centered around exploiting the role viruses play in cancer formation and progression. Headquartered in Cardiff, California, Viracta is at the forefront of advancing novel treatments in precision oncology, primarily targeting cancers associated with the Epstein-Barr Virus (EBV).
Products and Services
- Nana-val
Nana-val is Viracta Therapeutics’ flagship product candidate, representing a pioneering approach in the treatment of virus-associated cancers. This all-oral combination therapy marries the company's proprietary investigational drug, nanatinostat, with the antiviral agent valganciclovir. Designed to target Epstein-Barr virus-positive (EBV+) cancers, Nana-val is undergoing rigorous testing in various clinical trials. Key among these is the NAVAL-1 trial, an open-label Phase 2 basket trial aimed at treating multiple subtypes of relapsed/refractory EBV+ lymphoma. Additionally, Nana-val is being tested in an open-label Phase 1b/2 trial for EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors, highlighting its potential as a versatile treatment option for a range of virus-associated cancers.
- Vecabrutinib
Vecabrutinib is another significant product candidate in Viracta’s arsenal, currently in the clinical-stage of development. While specific details about its therapeutic targets and clinical trial progress are not extensively detailed, vecabrutinib represents Viracta's expansion into diverse areas of precision oncology, reflecting the company's commitment to developing a broad portfolio of targeted cancer therapies.
- VRx-510
Marking Viracta’s exploratory journey into early-stage research, VRx-510 is a preclinical product candidate. Though it's in the nascent stages of development, VRx-510 underscores Viracta's dedication to innovation and the expansion of its product pipeline. By investing in the research and development of VRx-510, Viracta is laying the groundwork for future therapeutic advancements in the field of virus-associated cancers.
